Adherex Technologies (FENC) Projected to Post Earnings on Wednesday

Adherex Technologies (NASDAQ:FENC) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of $0.0423 per share and revenue of $14.7490 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 8:30 AM ET.

Adherex Technologies (NASDAQ:FENC) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.18). The firm had revenue of $13.78 million during the quarter, compared to analyst estimates of $14.73 million. On average, analysts expect Adherex Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adherex Technologies Stock Performance

NASDAQ FENC opened at $6.02 on Wednesday. The stock has a 50 day moving average price of $7.91 and a 200-day moving average price of $8.14. Adherex Technologies has a one year low of $4.68 and a one year high of $9.92. The company has a market capitalization of $206.85 million, a P/E ratio of -26.17 and a beta of 0.75.

Insiders Place Their Bets

In related news, Director Rosty Raykov sold 10,349 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $7.76, for a total value of $80,308.24. Following the completion of the sale, the director directly owned 98,477 shares in the company, valued at $764,181.52. This trade represents a 9.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.98% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Adherex Technologies stock. Jane Street Group LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,718 shares of the company’s stock, valued at approximately $90,000. Jane Street Group LLC owned 0.05% of Adherex Technologies at the end of the most recent quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

More Adherex Technologies News

Here are the key news stories impacting Adherex Technologies this week:

• Neutral Sentiment: Short interest prints showed 0 shares and a 0.0 days-to-cover ratio across multiple March filings — figures appear inconsistent or erroneous and are unlikely to reflect real short activity; this data glitch can add volatility but doesn’t indicate bearish conviction on its own.
• Neutral Sentiment: A GlobeNewswire business update reporting strong PEDMARK ® product sales and record annual revenue pertains to Fennec Pharmaceuticals (ticker FENC) and may have been conflated with Adherex in some feeds, adding to ticker-level noise. Fennec Press Release
• Negative Sentiment: Adherex reported Q4 EPS of ($0.17), missing the consensus of $0.01, and revenue of $13.78M vs. estimates of $14.73M — a clear earnings and top-line miss that explains selling pressure. Earnings/Transcript Press Release
• Negative Sentiment: Analyst coverage noted a larger-than-expected quarterly loss (Zacks cited a loss vs. estimates), reinforcing the market reaction to the earnings miss. Zacks Article
• Negative Sentiment: A Johnson Fistel notice invites Fennec Pharmaceuticals shareholders to contact the firm about potential securities claims — the announcement targets Fennec (same ticker) and could be misattributed to Adherex, amplifying sell pressure due to legal‑risk headlines even if not applicable. Legal Notice

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Piper Sandler assumed coverage on shares of Adherex Technologies in a research report on Friday, January 9th. They set an “overweight” rating and a $18.00 price objective for the company. Wall Street Zen downgraded shares of Adherex Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. Zacks Research raised shares of Adherex Technologies from a “strong sell” rating to a “hold” rating in a report on Friday, December 12th. Finally, B. Riley Financial assumed coverage on shares of Adherex Technologies in a report on Thursday, February 12th. They issued a “buy” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.25.

Adherex Technologies Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.